Unique ID issued by UMIN | UMIN000015999 |
---|---|
Receipt number | R000018551 |
Scientific Title | A Clinical Study for Evaluating the Safety of Long-term Consumption of Food Containing Polydextrose A Randomized, Double-blind, Placebo-controlled, Parallel-group Study |
Date of disclosure of the study information | 2014/12/24 |
Last modified on | 2021/02/18 13:51:27 |
A Clinical Study for Evaluating the Safety of Long-term Consumption of Food Containing Polydextrose
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study
A Clinical Study for Evaluating the Safety of Long-term Consumption of Food Containing Polydextrose
A Clinical Study for Evaluating the Safety of Long-term Consumption of Food Containing Polydextrose
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study
A Clinical Study for Evaluating the Safety of Long-term Consumption of Food Containing Polydextrose
Japan |
No(subjects with fasting serum triglyceride levels 30-199 mg/dL)
Adult |
Others
NO
To evaluate the safety of long-term consumption of food containing polydextrose for 12 weeks
Safety
Biochemical examination, Hematological examination, urine analysis, vital signs
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
Food |
Food containing polydextrose
Food not containing polydextrose
20 | years-old | <= |
65 | years-old | > |
Male and Female
(1)Healthy males and females aged 20 to 64 years old
(2)Subjects whose fasting serum triglyceride levels are from 30 mg/dL to 199 mg/dL
(3)Subjects who can stop drinking from 2 days before each measurement
(4)Subjects who can make self-judgment and are voluntarily giving written informed consent
(1)Subjects who use medications affecting obesity, hyperlipidemia, lipid metabolism, and so on
(2)Subjects who can't stop using supplements and/or functional foods affecting obesity, hyperlipidemia, lipid metabolism, and so on
(3)Subjects who contract serious diabetes, kidney disease, liver disease, and/or disease needing immediate treatment, and who are taking relevant medicines
(4)Subjects who have a history of digestive disease affecting digestion and absorption, and related surgery
(5)Subjects who are under treatment for or have a history of drug addiction and/or alcoholism
(6)Subjects who have been diagnosed as familial hyperlipidemia
(7)Subjects who are planning to become pregnant after informed consent for the current study or are pregnant or lactating
(8)Subjects who have donated blood components and/or blood a volume of 200 mL and over within one month prior to the current study
(9)Subjects who are planning to participate or already participating in other clinical studies
(10)Subjects who are judged as
unsuitable for the study by the investigator for other reasons
30
1st name | YASUO |
Middle name | |
Last name | THO |
Medical Corporation Association KUNWA-KAI AIWA CLINIC
Medical office
343-0827
1-590-1 Kawayanagicho, Koshigaya-shi, Saitama
048-989-2000
kunwakai@aol.com
1st name | Yoshika |
Middle name | |
Last name | Komori |
KSO Corporation
Sales department
105-0023
1-9-7 Shibaura, Minato-ku, Tokyo
03-3452-7733
yoshi@kso.co.jp
KSO Corporation
TOYO SHINYAKU Co., Ltd
Profit organization
AIWA CLINIC institutional review board
1-590-1 Kawayanagicho,Koshigaya-shi, Saitama-ken 343-0827Japan
048-989-2000
kunwakai@aiwacl.or.jp
NO
2014 | Year | 12 | Month | 24 | Day |
Unpublished
Completed
2014 | Year | 11 | Month | 25 | Day |
2014 | Year | 12 | Month | 25 | Day |
2014 | Year | 12 | Month | 19 | Day |
2021 | Year | 02 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018551